New PET scan tracer aims to spot blood cancers more clearly
NCT ID NCT07670949
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors better than the standard FDG tracer. Thirty participants will receive one injection and have four scans over two hours, plus a follow-up FDG scan a few days later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-EV203 injection (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this could lead to a more accurate imaging method for detecting certain blood cancers, potentially improving diagnosis and treatment planning.
What could go wrong
This is an early-phase study with only 30 participants, so results may not apply to everyone. The new tracer may not prove significantly better than existing scans, and there are unknown risks from the radioactive injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••